MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

Pliant Therapeutics Inc

Closed

1.36 13.33

Overview

Share price change

24h

Current

Min

1.19

Max

1.4

Key metrics

By Trading Economics

Income

-6.4M

-56M

Employees

171

EBITDA

-10M

-59M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+572.27% upside

Dividends

By Dow Jones

Next Earnings

5 sie 2025

Market Stats

By TradingEconomics

Market Cap

-20M

77M

Previous open

-11.97

Previous close

1.36

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Pliant Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

9 lip 2025, 15:46 UTC

Major Market Movers

BitMine Shares Fall After Closing of $250 Million Private Placement

9 lip 2025, 23:44 UTC

Market Talk

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

9 lip 2025, 23:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9 lip 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

9 lip 2025, 22:59 UTC

Market Talk

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

9 lip 2025, 22:59 UTC

Market Talk

Global Equities Roundup: Market Talk

9 lip 2025, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

9 lip 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 lip 2025, 20:26 UTC

Earnings

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

9 lip 2025, 19:18 UTC

Market Talk

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

9 lip 2025, 19:03 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

9 lip 2025, 18:31 UTC

Market Talk

Some Fed Officials Supported Considering July Cut -- Market Talk

9 lip 2025, 17:07 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

9 lip 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk -2-

9 lip 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9 lip 2025, 16:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

9 lip 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 lip 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9 lip 2025, 16:14 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9 lip 2025, 16:14 UTC

Market Talk

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

9 lip 2025, 16:14 UTC

Acquisitions, Mergers, Takeovers

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

9 lip 2025, 16:12 UTC

Market Talk

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

9 lip 2025, 16:08 UTC

Market Talk

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

9 lip 2025, 15:31 UTC

Major Market Movers

BitMine Shares Fall After Closing of $250M Private Placement

9 lip 2025, 15:31 UTC

Market Talk
Acquisitions, Mergers, Takeovers

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

9 lip 2025, 15:27 UTC

Market Talk

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

9 lip 2025, 14:36 UTC

Acquisitions, Mergers, Takeovers

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

9 lip 2025, 14:31 UTC

Acquisitions, Mergers, Takeovers

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

9 lip 2025, 14:26 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

9 lip 2025, 14:26 UTC

Market Talk

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Peer Comparison

Price change

Pliant Therapeutics Inc Forecast

Price Target

By TipRanks

572.27% upside

12 Months Forecast

Average 8 USD  572.27%

High 17 USD

Low 3 USD

Based on 6 Wall Street analysts offering 12 month price targets forPliant Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

6 ratings

1

Buy

5

Hold

0

Sell

Technical Score

By Trading Central

1.43 / 1.6Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.